If you or your child has been diagnosed with acute lymphoblastic leukemia (ALL), you or they might be able to take part in a research study. This study aims to understand why there are differences in outcomes in adolescents and young adults treated for ALL.
The purpose of this research study is to learn whether there are pre-treatment factors that impact quality of life and function 3 years or more after primary treatment of breast cancer. The factors we will look at in this study may include patient characteristics, specific breast cancer diagnosis, treatments, toxicities or adverse events during treatment.
If you are receiving your cancer treatment at an infusion space in North Carolina Basnight Cancer Hospital (NCBCH), you may be able to take part in a research study. This study aims to understand your satisfaction and experience in the infusion spaces during your treatment.
This study will check muscle mass, physical function, and cancer-related aging in children and young adults (8-21 years old) undergoing cancer treatment. In this study, we want to learn how muscle and physical function (strength, mobility, endurance) change in children and young adults who undergoing cancer treatment and how to measure these changes.
Do you have asymptomatic multiple myeloma, also known as smoldering multiple myeloma? You may be able to take part in a research study to help us learn more about the effectiveness of a drug called daratumumab in combination with lenalidomide and steroids.
Do you have relapsed or refractory multiple myeloma? Have you received at least one type of treatment? If so, you may be able to take part in a research study looking at the the safety of giving an investigational medication to patients with multiple myeloma.
This study is being done to answer the following question: What are the effects (good or bad) of adding a study drug (duvelisib or CC-486 (azacitidine)) to the usual combination of drugs? We are doing this study because we want to find out if this approach is better or worse than the usual approach for T-cell lymphoma. The usual approach is defined as care most people get for peripheral T-cell lymphoma.
Have you been diagnosed with oropharyngeal (tonsil or tongue base) cancer. If so, you may be able to take part in a research study testing markers to determine who may be appropriate for less aggressive therapy and markers to determine if recurrent tumors can be detected earlier.
In this study, we want to learn more about the safety and tolerability of a drug called NX-1607 in adult patients with advanced tumors. We want to see if this new drug may be able to slow the growth of your cancer.
Have you been diagnosed with an advanced cancer that has not responded to or has stopped responding to treatment? Have you had genetic testing done on your cancer? If so you may be able to take park in a research study to observe how certain cancer drugs target tumor DNA. Travel reimbursement provided.